Accutar Starts China Phase I Trial of AI-developed Protein Degrader for Breast Cancer

Accutar Biotechnology, an AI-based New Jersey-Shanghai drug discovery company, has dosed the first patient in a China Phase I trial of AC0682, an orally bioavailable chimeric degrader molecule designed to target ERα protein with high potency and selectivity. ERα is a hormone-regulated transcription factor that plays a critical role in breast cancer initiation and proliferation.  Accutar’s proprietary AI platform uses an innovative universal force-field-based modeling methodology that reduces the average preclinical drug discovery time to one year.  Earlier this year, the company started trials China of an AR degrader for prostate cancer. More details....

Share this with colleagues: